The ORIGIN study is a multidisciplinary endeavor, blending expertise from ten different specialties within the Mount Sinai Health System to analyze an extraordinary resource: the Department of Defense Serum Repository (DoDSR). This repository contains millions of longitudinal blood samples collected from active-duty U.S. military personnel decades before disease onset. By leveraging advanced omics techniques—including proteomics, exposomics, metabolomics, and genomics—the researchers intend to detect early molecular signatures and unravel the biological pathways that foreshadow a wide spectrum of chronic diseases.

Dr. Jean-Frédéric Colombel, a professor of medicine and co-director of the Helmsley Inflammatory Bowel Disease Center at Mount Sinai, emphasized the potential of this research to revolutionize clinical care. “We’ve long envisioned a future where clinicians can anticipate disease and intervene preemptively,” he explains. ORIGIN builds on over ten years of collaboration with USU, where initial studies pinpointed molecular markers that appeared in blood years prior to inflammatory bowel disease diagnosis. The scale and scope now vastly surpass these preliminary efforts, with more than 25 diseases under simultaneous investigation.

ORIGIN’s research portfolio encompasses autoimmune conditions like rheumatoid arthritis, lupus, and multiple sclerosis; neurodegenerative disorders; several cancers including early-onset colon and lung cancer; and psychiatric conditions such as post-traumatic stress disorder (PTSD). The inclusion of such a diverse set of diseases reflects a novel approach, aiming to detect common molecular threads that may underlie seemingly disparate illnesses and to ultimately redefine disease classification through a molecular lens rather than by affected organ systems.

What sets ORIGIN apart is its integration within the Precision Immunology Institute at Mount Sinai (PrIISM), a unique consortium designed to dismantle traditional departmental silos. Cardiologists, immunologists, oncologists, neurologists, and environmental scientists collaborate closely, bringing their specialized knowledge to bear on shared pathological mechanisms. Such cross-disciplinary synergy, paired with state-of-the-art computational modeling, seeks to unravel complex biological networks that govern disease emergence and progression.

The use of military service members as subjects presents an unparalleled scientific opportunity. Because active-duty personnel undergo systematic, periodic health evaluations and blood draws, their archived samples in the DoDSR capture the dynamic biological milieu of individuals years before clinical symptoms arise. This longitudinal framework allows investigators to chart molecular changes over time and correlate them with future disease diagnoses, offering unprecedented insight into disease etiology and trajectory.

Of particular interest are environmental exposures unique to military contexts, such as contact with burn pits and per- and polyfluoroalkyl substances (PFAS), known colloquially as “forever chemicals” due to their persistence. These toxins are present at numerous U.S. military installations and could play crucial roles in modifying immune function or increasing cancer risk. ORIGIN’s exposomics approach endeavors to decode how such exposures alter human biology at the molecular level, potentially unveiling novel preventive strategies.

The data governance and analytic infrastructure supporting ORIGIN is state-of-the-art. USU data analysts meticulously curate and de-identify records, ensuring patient privacy while facilitating robust matched case-control comparisons. The integration of the Military Health System Data Repository with DoDSR’s biospecimens enables sophisticated bioinformatics analyses that correlate clinical outcomes with molecular data, charting the earliest molecular fingerprints of disease.

In the words of Dr. Daniel J. Adams, USU’s Principal Investigator for ORIGIN, “This collaboration advances our mission to optimize the readiness and health of our military community through groundbreaking scientific discovery.” The findings promise to inform not only military medicine but also have widespread civilian implications, particularly as the incidence of several targeted conditions accelerates in younger populations.

ORIGIN’s decade-spanning timeline and vast sample repository set the stage for longitudinal discovery. By analyzing specimens collected from 2003 through 2025, the consortium hopes to continually refine its understanding of preclinical biology and apply these insights to develop predictive biomarkers and precision interventions. The resulting molecular atlas of disease initiation could revolutionize clinical guidelines, drug development pipelines, and public health strategies.

The technical architecture of ORIGIN mirrors the complexity of the diseases under study. Proteomics explores the changing landscape of proteins that execute cellular functions; metabolomics reveals metabolic shifts that may signify cellular stress or dysfunction; genomics provides the foundational code underlying disease susceptibility; and exposomics integrates environmental variables. Together, these omics layers will be analyzed via advanced computational methods to generate predictive models capable of anticipating disease onset with unprecedented accuracy.

A key ambition of the project is to identify convergent molecular pathways shared among multiple diseases, paving the way for therapies that simultaneously target these common mechanisms rather than isolated symptoms. This systems biology perspective—facilitated by the collaborative spirit of PrIISM—has the potential to redefine medical paradigms and foster a new era of personalized, preventive healthcare applicable to both military and civilian populations worldwide.

Mount Sinai’s leadership role in this initiative aligns with its stature as a leading academic medical institution. The Health System’s enormous clinical and research infrastructure, including multiple hospitals, outpatient facilities, and a top-ranked medical school, provides a fertile environment for innovation. Furthermore, the robust tradition of integrating cutting-edge technologies such as artificial intelligence and large-scale data analytics underpins ORIGIN’s ambitious goals.

As the ORIGIN study progresses, its findings are poised to yield profound insights that extend beyond academic knowledge. They may lead to novel diagnostic platforms capable of identifying at-risk individuals early, new therapeutics designed to intercept disease processes before irreparable damage, and tailored preventive strategies that consider both genetic predispositions and environmental factors. Ultimately, ORIGIN aspires to transform medicine from a reactive model that treats symptoms to a predictive science that preserves health.

In summary, ORIGIN represents a visionary leap forward in biomedical research. By leveraging the unique longitudinal resources of the military, integrating multi-omics technologies, and fostering unprecedented interdisciplinary collaboration, the project stands to illuminate the molecular origins of chronic illnesses. This research will not only enhance the health and readiness of military personnel but also provide a blueprint for healthcare innovation benefiting global populations.

Subject of Research: People

Article Title: ORIGIN Initiative Pioneers Preclinical Omics Analysis to Predict and Prevent Chronic Diseases

News Publication Date: March 2, 2026

Web References:

• Mount Sinai Health System: https://www.mountsinai.org
• Mount Sinai on Facebook: https://www.facebook.com/mountsinainyc
• Mount Sinai on Instagram: https://www.instagram.com/mountsinainyc
• Mount Sinai on LinkedIn: https://www.linkedin.com/company/mountsinainyc
• Mount Sinai on X (Twitter): https://twitter.com/mountsinainyc
• Mount Sinai on YouTube: https://www.youtube.com/mountsinainy

Keywords: preventive medicine, gastroenterology, neurology, oncology, cardiology, multi-omics, proteomics, metabolomics, genomics, exposomics, molecular medicine, military medicine, chronic disease, inflammatory bowel disease, autoimmune diseases, early cancer detection, post-traumatic stress disorder, interdisciplinary collaboration, precision immunology

This ambitious investigation integrates multi-layered datasets, including proteomic quantitative trait loci (pQTL) data drawn from approximately 1,348 plasma proteins in the ARIC cohort alongside genome-wide association study (GWAS) summary statistics for 19 distinct cardiovascular diseases procured from FinnGen and 82 CMR-derived phenotypes from the UK Biobank. This meticulous design allows an unprecedented high-resolution molecular dissection of CVD pathogenesis, bridging genetic associations, protein expression, and structural heart traits demarcated through advanced imaging.

Initially, a proteome-wide association study (PWAS) scanned the landscape to pinpoint protein-disease correlations across the cardiovascular clinical phenotypes and magnetic resonance imaging traits. Following this, Mendelian randomization (MR) and colocalization analyses were deployed to differentiate correlation from causality, a critical distinction to prioritize protein targets that plausibly contribute to disease mechanisms rather than simply reflecting downstream effects. Importantly, this pipeline included an external layer of replication through the independent deCODE genetics dataset, strengthening the robustness of these discoveries.

The results were compelling, unveiling 342 significant protein-CVD associations and 115 protein-CMR relationships in the discovery phase. MR and colocalization trimmed these to 66 and 39 putative causal pairs respectively. The replication analysis further bolstered confidence by validating 51 protein-disease and 33 protein-imaging associations. Among these, four plasma proteins—AGER, CCN3, FER, and SPON1—emerged as particularly striking candidates due to their consistent genetic linkage with both clinical cardiovascular events such as myocardial infarction (MI) and aortic aneurysm (AA), and intermediate imaging phenotypes like left ventricular cardiac output (LVCO) and left ventricular end-systolic volume (LVESV).

AGER (advanced glycosylation end product-specific receptor), known for mediating inflammatory responses, was implicated through its plasma abundance in modulating structural and functional cardiac remodeling. Likewise, CCN3 (cellular communication network factor 3), a matricellular protein influencing cell adhesion and signaling, was identified as a nexus point between extracellular matrix dynamics and cardiovascular health. FER, a non-receptor tyrosine kinase with emerging roles in immune regulation, demonstrated differential expression at single-cell resolution in aortic tissue, especially within endothelial and smooth muscle cells, highlighting its plausible involvement in vascular integrity and inflammation. SPON1 (spondin-1), an extracellular matrix protein with functions in cell adhesion and neural development, also showed promising associations, warranting further biological exploration.

The incorporation of cardiovascular magnetic resonance imaging added a transformative dimension to this omics study. CMR provides exquisitely detailed phenotyping of cardiac morphology and function beyond traditional clinical diagnoses, enabling the capture of subclinical and intermediate traits. By relating plasma protein levels to quantitative CMR metrics, this study elucidated not only disease associations but also underlying pathophysiological mechanisms, bridging molecular and anatomical domains.

Single-cell RNA sequencing analyses further enriched the context by delineating the cellular specificity of critical proteins within cardiovascular tissues. This high-resolution cellular map revealed, for instance, how FER expression varies among vascular cell types, supporting roles in both vascular remodeling and immune cell interactions. Such insights deepen mechanistic understanding and open avenues for targeted interventions that modulate specific cell populations in the cardiovascular milieu.

From a translational perspective, the study advances the burgeoning field of cardio-immunology by linking systemic immune-related proteins to cardiovascular structure and disease risk. This integrative framework offers a compendium of prioritized plasma proteins that could serve as therapeutic targets or biomarkers, potentially accelerating drug development pipelines. Moreover, by leveraging genetic instruments and large-scale biobanks, the approach circumvents common pitfalls of confounding and reverse causation that have long plagued observational research.

However, the researchers prudently acknowledge several limitations. The cohorts studied predominantly consist of individuals of European ancestry, underscoring the need for validation in diverse populations to ensure generalizability and equity in therapeutic advances. Additionally, while the multi-omics approach robustly implicates proteins in disease processes, functional experiments remain essential to unravel precise molecular mechanisms and to test pharmacologic modifiability.

Looking forward, the integration of cardiovascular imaging with omics modalities represents a powerful paradigm for biomarker discovery and drug target prioritization. This fusion of genomic, proteomic, and phenotypic data elevates precision medicine efforts in cardiology, enabling stratification of disease subtypes and personalized therapy strategies. As cardiovascular diseases continue to represent a global health burden, such innovative methodologies pave the way toward more effective prevention and treatment, moving beyond traditional risk factor frameworks.

In conclusion, this landmark study exemplifies how comprehensive multi-omics coupled with advanced imaging can unravel the intricate biological networks underlying cardiovascular diseases. By spotlighting druggable plasma proteins like AGER, CCN3, FER, and SPON1, it charts a promising course for future research and therapeutic innovation. The findings herald a new era in cardiovascular medicine, where integrative analyses illuminate pathogenesis and catalyze breakthroughs against this pervasive, devastating group of diseases.

Subject of Research: Not applicable

Article Title: Integrative omics analysis incorporating cardiovascular magnetic resonance imaging pinpoints potentially druggable plasma proteins for cardiovascular diseases

News Publication Date: 7-Jan-2026

Web References: http://dx.doi.org/10.1093/lifemeta/loag001

Image Credits: HIGHER EDUCATION PRESS

Keywords: Cell biology